Mary Ellen Perry, Ph.D., Program Leader

1
Special NIH Funding Opportunities

• Mary Ellen Perry, Ph.D., Program Leader
• Office of Strategic Coordination
• Division of Program Coordination, Planning, and
  Strategic Initiatives
• NIH Office of the Director

2
27 NIH Institutes and Centers
3
The Office of the Director (OD)
4

• Strategic Priorities
• High-throughput Technologies
• Translational Medicine
• Science for Health Care Reform
• Global Health
• Reinvigorating and Empowering the Biomedical
  Research Community

Francis S. Collins, M.D., Ph.D. NIH Director
5

• Established
• the Common Fund to support cross-cutting,
  trans-NIH programs
• the Division of Program Coordination, Planning,
  and Strategic Initiatives (DPCPSI)

6
In FY2010, the Common Fund was 544M. The
Common Fund currently supports a series of short
term, high impact, trans-NIH programs, some of
which were previously called Roadmap
programs.
James M. Anderson, M.D., Ph.D. DPCPSI Director
7
27 active programs!
8
Five Special Funding Opportunities
Eureka!
9
Reinvigorating and Empowering the Biomedical
Research Community
We must develop ways to liberate our brightest
minds to pursue high-risk, high-reward ideas
during their most creative years.
Nature, Vol.467, 7 October 2010.
10
Age Distribution of R01-equivalent Principal
Investigators
All Investigators
First-Time Investigators
FY2007 Data
Average Age All Investigators
51.0 First-Time Investigators 42.6
Percent of Total
Age
11
How can we shorten the time to first grant?
12

• Early Independence Award Program
• Graduate students and clinicians within one year
  of degree
• Up to 250K DC/year for five years, plus FA
• Talented young scientists who have the intellect,
  scientific creativity, drive and maturity to
  flourish independently without the need for
  traditional post-doctoral training
• FOA RM10-019
• January 21, 2011 receipt

http//nihroadmap.nih.gov/
13
Reinvigorating and Empowering the Biomedical
Research Community
New Innovator program addresses two important
goals stimulating highly innovative research and
supporting promising new investigators (167
awards since 2007).
Pioneer Awards support individual scientists of
exceptional creativity who propose pioneering
approaches to major challenges in biomedical and
behavioral research (98 awards since 2004).
Transformative R01 program places the emphasis on
creative ideas - projects with the potential to
create or overturn paradigms (62 awards since
2009).
http//nihroadmap.nih.gov/
14

• New Innovator Award
• Unusually creative investigators with a highly
  innovative research idea
• 300K DC/year for five years, plus FA
• New and early stage investigators
• FOA RM10-009
• Due date September 20, 2010

http//nihroadmap.nih.gov/
15
New Innovators in cancer research
Jianjun Cheng University of Illinois at
Urbana-Champaign Developing Clinically
Applicable, Cancer-Targeting Polymeric
Nanoconjugates
Conor Evans Massachusetts General
Hospital/Harvard Medical School Imaging and
Overcoming Hypoxia-Induced Resistance in
Metastatic Ovarian Cancer
Monica Guzman Cornell University /Weill Medical
College Selection of Novel Therapies to Ablate
Chemoresistant Myeloid Leukemia Stem Cells
Benjamin Garcia Princeton University Novel
Methodology for Quantitative High-throughput
Cancer Epigenetics
http//nihroadmap.nih.gov/
16

• Pioneer Award Program
• Any qualified investigator
• 500K DC/year for five years, plus FA
• Individual scientists of exceptional creativity
  who propose pioneering and possibly transforming
  approaches to addressing major biomedical or
  behavioral challenges
• FOA RM10-008
• Due date September 13, 2010

http//nihroadmap.nih.gov/
17
Some Pioneers of interest
Leona Samson Massachusetts Institute of
Technology Developing Novel Methods to Measure
DNA Repair Capacity in Human Populations
Michael Roukes California Institute of
Technology Nanoscale Tools to Push Biomedical
Frontiers
Susan Rosenberg Baylor College of
Medicine Forward Genomics of Damage Control An
Undiscovered Class of Cancer Genes
Joseph Nadeau The Institute for Systems
Biology Lamarck Redux Transgenerational Genetic
Effects on Phenotypes and Disease
http//nihroadmap.nih.gov/
18

• Transformative RO1
• Anyone with a project to overturn or create a
  paradigm
• Up to 25M TC for five years
• Out of the box ideas
• FOA RM10-010
• October 27, 2010 receipt

http//nihroadmap.nih.gov/
19
Some TRO1 projects of interest
GEORGE COUKOS University of Pennsylvania Transfo
rmative Personalized Vascular Disrupting Cancer
Immunotherapy
RICHARD FLAVELL MADHAV DHODAPKAR MARKUS MANZ
Yale University and University Hospital
Zurich Understanding Hematopoietic Neoplasias
Using Humanized Mice
http//nihroadmap.nih.gov/
20
Reinvigorating and Empowering the Biomedical
Research Community
New Innovator Program address two important
goals stimulating highly innovative research and
supporting promising new investigators (167
awards since 2007).
Pioneer Awards support individual scientists of
exceptional creativity who propose pioneering
approaches to major challenges in biomedical and
behavioral research (98 awards since 2004).
Transformative R01 Program places the emphasis on
creative ideasprojects with the potential to
create or overturn paradigms. (62 awards since
2009).
21
Trans-NIH but not Common Fund

• Exceptional, Unconventional Research Enabling
  Knowledge Acceleration (EUREKA) (R01) Program
• Open to anyone with a high impact project
• Exceptionally innovative research on novel
  hypotheses or difficult problems, solutions to
  which would have an extremely high impact on
  biomedical or bio-behavioral research
• Up to 800K DC for four years, plus FA
• FOA GM10-009
• November 24, 2010 receipt

22
Institutes participating in EUREKA awards
23
                 
NCI Eureka awardee 2010
Our plan is to deliver the tumor to the drug --
by directing tumor cells to a specially
engineered gel that can be removed or designed to
kill the cells -- rather than the current
strategy of delivering the drug to the tumor,
which is problematic due to the irregular
vasculature and poor diffusivity of the tumor
tissue, explained Bellamkonda, who is also a
Georgia Cancer Coalition Distinguished Scholar.
Ravi Bellamkonda, Ph.D. Georgia Institute of
Technology
24
Summary Special Opportunities
Program Eligibility
Early Independence Award Graduate student or new
clinician New Innovator New PI/ESI with
innovative project Pioneer Very creative
investigator TR01 Person with paradigm
disrupting idea Eureka award Person with a
very innovative project
25
(No Transcript)
26
For more information
http//nihroadmap.nih.gov/
Contact information Todays talk Mary Ellen
Perry perryma_at_mail.nih.gov Pioneer, TR01, New
Innovators, Early Independence Award Ravi
Basavappa basavapr_at_od.nih.gov Eureka awards
Judy Mietz mietzj_at_mail.nih.gov Common Fund
Ellie Murcia murciae_at_od.nih.gov
27
(No Transcript)